Article
Genetically Proxied Inhibition of Cholesterol-Lowering Drug Targets and Survival in HPV-Positive and Non-HPV-Driven Head and Neck Cancer: A Multicentre MR Study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Sept 2026
Cheng Danni, Hueniken Katrina, Hou Tianzhichao, Shu Tao, Espin-Garcia Osvaldo, Dudding Tom, Gormley Mark, McKay James D, de Almeida John R, Hope Andrew J, Spreafico Anna, Huang Shao Hui, Schroeder Lea, Waterboer Tim, Hayes D Neil, Virani Shama, Brennan Paul, Pring Miranda, Olshan Andrew F, Diergaarde Brenda, Macfarlane Gary J, Lagiou Pagona, Lagiou Areti, Polesel Jerry, Agudo Antonio, Alemany Laia, Ahrens Wolfgang, Healy Claire M, Conway David I, Canova Cristina, Holcatova Ivana, Ren Jianjun, Zhao Yu, Hung Rayjean J, Mondul Alison M, Xu Wei, Liu Geoffrey
Abstract excerpt
BACKGROUND: Cholesterol pathways may influence head and neck squamous cell carcinoma (HNSCC) progression, but evidence on prognosis is inconsistent. We used Mendelian randomization (MR) to test whether genetically proxied inhibition of major low-density lipoprotein cholesterol (LDL-C)-lowering drug targets and circulating lipid traits affects overall survival (OS) in HPV-positive and non-HPV-driven HNSCCs....
Read the complete abstract on PubMedTopics
- Humans